Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

286 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-17

Study Completion Date

2016-09-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate of efficacy and safety of cilinidipine plus valsartan and valsartan alone in patients with essential hypertension inadequately controlled on valsartan monotherapy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension

NCT00413413

Hypertension

COMPLETED PHASE3

A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination Tablet With Coadministration of Cilnidipine and Valsartan

NCT02088008

Healthy Volunteers

UNKNOWN PHASE1

A Drug Interaction Study of Cilnidipine and Valsartan

NCT01838967

Healthy

COMPLETED PHASE1

Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension

NCT00413049

Hypertension

COMPLETED PHASE3

A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan

NCT02343250

Hypertension

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A

cilinidpine 10mg + valsartan 160mg

Group Type EXPERIMENTAL

valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg

Intervention Type DRUG

Arm B

cilnidipine 5mg + valsartan 160mg

Group Type EXPERIMENTAL

valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg

Intervention Type DRUG

Arm C

valsartan 160mg

Group Type ACTIVE_COMPARATOR

valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* essential hypertension patients whose blood pressure is not controlled before the study (sDBP≥90mmHg for drug-treated patients, sDBP≥95mmHg for drug-naive patients)